

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trudemark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/771,708	01/30/2001	Shankar Balasubramanian	106632	9485	
75	590 09/09/2002				
Oliff & Berridge, PLC POST OFFICE BOX 19928			EXAMINER		
Alexandria, VA			FORMAN,	FORMAN, BETTY J	
			ART UNIT	PAPER NUMBER	
			1634	1/	
			DATE MAILED: 09/09/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Summers	09/771,708	BALASUBRAMANIAN ET AL.				
Office Action Summary	Examiner	Art Unit				
	BJ Forman	1634				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the o	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	66(a). In no event, however, may a reply be tin within the statutory minimum of thirty (30) day rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on 20 J	<u>une 2002</u> .					
2a) This action is FINAL . 2b) ⊠ Thi	s action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4)⊠ Claim(s) 43-51 is/are pending in the applicatio	n					
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>43-51</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner	•					
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.						
Applicant may not request that any objection to the	e drawing(s) be held in abeyance. S	ee 37 CFR 1.85(a).				
11) The proposed drawing correction filed on	_is: a)	oved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
Copies of the certified copies of the prior application from the International But See the attached detailed Office action for a list.	reau (PCT Rule 17.2(a)).					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language pro	visional application has been rec	ceived.				
Attachment(s)	. ,					
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 3. 	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)				

Art Unit: 1634

DETAILED ACTION

Election

1. Applicant's election of Group I, Claims 1-15 in Paper No. 15 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Applicant's Preliminary Amendment of Paper No. 15 which canceled Claims 1-42 and added new Claims 43-51 is acknowledged.

Claims 43-51 are pending.

Priority

2. The foreign priority claim filed on 4 June 2001 was not entered because the foreign priority claim was not filed during the time period set forth in 37 CFR 1.55(a)(1). For original applications filed under 35 U.S.C. 111(a) (other than a design application) on or after November 29, 2000, and any applications which applicant has requested voluntary publication, the time period is during the pendency of the application and within the later of four months from the actual filing date of the application or sixteen months from the filing date of the prior foreign application. For applications that have entered national stage from an international application filed on or after November 29, 2000, after compliance with 35 U.S.C. 371, the claim for priority must be made during the pendency of the application and within the time limit set forth in the PCT and the Regulations under the PCT. See 37 CFR 1.55(a)(1)(ii). If applicant desires priority under 35 U.S.C. 119(a)-(d), (f) or 365(a) based upon a prior foreign application, applicant must file a petition for an unintentionally delayed priority claim (37 CFR

Art Unit: 1634

1.55(c)). The petition must be accompanied by (1) a surcharge under 37 CFR 1.17(t), and (2) a statement that the entire delay between the date the claim was due under 37 CFR 1.55(a)(1) and the date the claim was filed was unintentional. The Commissioner may require additional information where there is a question whether the delay was unintentional. The petition should be directed to the Office of Petitions, Box DAC, Assistant Commissioner for Patents, Washington, D.C. 20231.

Applicant's claim for priority under 35 U.S.C. 119 as a CIP to PCT/GB99/02487 is acknowledged. However, the international application upon which priority is claimed fails to provide adequate support under 35 U.S.C. 112 for claims 43-51 of this application. Claims 43-51 are drawn to a device comprising an array of polynucleotide molecules wherein each molecule comprises a polynucleotide duplex covalently linked to form a hairpin loop structure. The international application to which Applicant claims priority does not disclose the device comprising polynucleotide duplexes covalently linked to form a hairpin loop structure as instantly claimed. Therefore, the '02487 application does not provide support under 35 U.S.C. 112 for the instant claims.

the '02487 application does not provide support under 35 U.S.C. 112 for the instant claims, the effective filing date for the instant claims is the actual filing date of the instant application i.e. 30 January 2001.

Information Disclosure Statement

3. The references listed on the 1449s received 27 April 2001 in Paper No. 3, 6 June 2001 in Paper No. 7, and 21 November 2001 in Paper No. 9 have been reviewed and considered.

Additionally, the International Search Report submitted with Paper No. 3 has been reviewed.

Claim Rejections - 35 USC § 112

Art Unit: 1634

4. The following is a quotation of the second paragraph of 35 U.S.C. 112:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

- 5. Claims 50 and 51 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- a. Claim 50 is indefinite for the recitation "at least one arrayed polynucleotide" because the recitation lacks proper antecedent basis in Claim 43 which does not recite "arrayed polynucleotide". It is suggested that Claim 50 be amended to provide proper antecedent basis e.g. delete "arrayed" and after "polynucleotide", insert "molecule immobilized on the solid support".
- b. Claim 51 is indefinite for the recitation "the arrayed polynucleotide" because the recitation lacks proper antecedent basis in Claim 43 which does not recite "arrayed polynucleotide". It is suggested that Claim 50 be amended to provide proper antecedent basis e.g. delete "arrayed" and after "polynucleotide", insert "molecule immobilized on the solid support".

Claim Rejections - 35 USC § 102

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Art Unit: 1634

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

7. Claims 43-51 are rejected under 35 U.S.C. 102(a) as being anticipated by Gunderson et al (EP 0 995 804 A2, published 26 April 2000).

Regarding Claim 43, Gunderson et al disclose a device comprising an array of polynucleotide molecules immobilized on a solid surface wherein each molecule comprises a polynucleotide duplex covalently linked to form a hairpin loop structure, one end of which comprises a target polynucleotide (i.e. probe) and the array has a surface density which allows the target polynucleotides to be individually resolved (page 9, ¶ 77-79; page 11, ¶ 100; and Fig. 1).

Regarding Claim 44, Gunderson et al disclose the device wherein immobilization to the solid surface is via covalent attachment (page 9, ¶ 77).

Regarding Claim 45, Gunderson et al disclose the device wherein adjacent molecules of the array are separated by a distance of at least 10µm i.e. each region upon which a distinct compound is synthesized is smaller than 1cm² and/or separated into wells (page 5, ¶ 40).

Regarding Claim 46, Gunderson et al disclose the device wherein adjacent molecules of the array are separated by a distance of at least 100µm i.e. each region upon which a distinct compound is synthesized is smaller than 1cm² and/or separated into wells (page 5, ¶ 40).

Regarding Claim 47, Gunderson et al disclose the device wherein adjacent molecules of the array are separated by a distance of at least 250µm i.e. each region upon which a distinct compound is synthesized is smaller than 1cm² and/or separated into wells (page 5, ¶ 40).

Regarding Claim 48, Gunderson et al. disclose the device having a density of from 10^6 to 10^9 molecules per cm² i.e. 10^4 to 10^6 per 0.25mm² (pages 9-10, ¶ 84).

Regarding Claim 49, Gunderson et al. disclose the device having a density of from 10^7 to 10^8 molecules per cm² i.e. 10^4 to 10^6 per 0.25mm² (pages 9-10, ¶ 84).

Art Unit: 1634

Regarding Claim 50, Gunderson et al disclose the device wherein at least one polynucleotide molecule on the array has a second polynucleotide hybridized thereto (pages 10-11, ¶ 92-94).

Regarding Claim 51, Gunderson et al disclose the device wherein the polynucleotides are of known sequence i.e. complete n-mers (page 9, ¶ 78-79).

8. Claims 43-51 are rejected under 35 U.S.C. 102(b) as being anticipated by Lockhart et al (WO 97/27317, published 13 July 1997).

Regarding Claim 43, Lockhart et al disclose a device comprising an array of polynucleotide molecules immobilized on a solid surface wherein each molecule comprises a polynucleotide duplex covalently linked to form a hairpin loop structure, one end of which comprises a target polynucleotide and the array has a surface density which allows the target polynucleotides to be individually resolved (Abstract; page 6, second full paragraph; page 70, line 26-page 72, line 12; and Fig. 13 and 14).

Regarding Claim 44, Lockhart et al disclose the device wherein immobilization to the solid surface is via covalent attachment (page 29, second full paragraph, lines 20-22).

Regarding Claim 45, Lockhart et al disclose the device wherein adjacent molecules of the array are separated by a distance of at least 10µm i.e. 60 different polynucleotides/cm² (page 7, second full paragraph).

Regarding Claim 46, Lockhart et al disclose the device wherein adjacent molecules of the array are separated by a distance of at least 100µm i.e. 60 different polynucleotides/cm² (page 7, second full paragraph).

Art Unit: 1634

Regarding Claim 47, Lockhart et al disclose the device wherein adjacent molecules of the array are separated by a distance of at least 250µm i.e. 60 different polynucleotides/cm² (page 7, second full paragraph).

Regarding Claim 48, Lockhart et al disclose the device having a density of from 106 to 10^9 molecules per cm² (page 30, second paragraph).

Regarding Claim 49, Lockhart et al disclose the device having a density of from 10⁷ to 10⁸ molecules per cm² (page 30, second paragraph).

Regarding Claim 50, Lockhart et al disclose the device wherein at least one polynucleotide molecule on the array has a second polynucleotide hybridized thereto (Fig. 13-14).

Regarding Claim 51, Lockhart et al disclose the device wherein the polynucleotides are of known sequence (Abstract).

9. Claims 43-47, 50 and 51 are rejected under 35 U.S.C. 102(b) as being anticipated by Lane et al. (WO 97/08183, published 6 March 1997).

Regarding Claim 43, Lane et al disclose a device comprising an array of polynucleotide molecules immobilized on a solid surface wherein each molecule comprises a polynucleotide duplex covalently linked to form a hairpin loop structure, one end of which comprises a target polynucleotide and the array has a surface density which allows the target polynucleotides to be individually resolved (page 8, first full paragraph, page 10, first full paragraph and Fig. 1).

Regarding Claim 44, Lane et al disclose the device wherein immobilization to the solid surface is via covalent attachment (page 9, first full paragraph, lines 10-15).

Application/Control Number: 09/771,708 Page 8

Art Unit: 1634

Regarding Claim 45, Lane et al disclose the device wherein adjacent molecules of the array are separated by a distance of at least 10µm i.e. within separate wells of a 96-well plate (page 10, first full paragraph, lines 15-19).

Regarding Claim 46, Lane et al disclose the device wherein adjacent molecules of the array are separated by a distance of at least 100µm i.e. within separate wells of a 96-well plate (page 10, first full paragraph, lines 15-19).

Regarding Claim 47, Lane et al disclose the device wherein adjacent molecules of the array are separated by a distance of at least 250µm i.e. within separate wells of a 96-well plate (page 10, first full paragraph, lines 15-19).

Regarding Claim 50, Lane et al disclose the device wherein at least one polynucleotide molecule on the array has a second polynucleotide hybridized thereto (Example 4, pages 18-19).

Regarding Claim 51, Lane et al disclose the device wherein the polynucleotides are of known sequence (i.e. complementary to a target sequence and Example 4, pages 18-19).

Claim Rejections - 35 USC § 103

10. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Art Unit: 1634

11. Claims 48-49 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lane et al (WO 97/08183, published 6 March 1997) in view of Lockhart et al (WO 97/27317, published 13 July 1997).

Regarding Claim 48 and 49, Lane et al teach a device comprising an array of polynucleotide molecules immobilized on a solid surface wherein each molecule comprises a polynucleotide duplex covalently linked to form a hairpin loop structure, one end of which comprises a target polynucleotide and the array has a surface density which allows the target polynucleotides to be individually resolved (page 8, first full paragraph, page 10, first full paragraph and Fig. 1) wherein the molecules are immobilized to a surface e.g. membrane (page 10, first full paragraph, lines 15-19) but they do not specifically teach the device has a density of 106 to 109 molecules per cm2 (claim 48) or a density of 106 to 109 molecules per cm2 (Claim 49). However, the claimed densities were well known in the art at the time the claimed invention was made as taught by Lockhart et al who teach a similar device having the claimed densities comprising an array of polynucleotide molecules immobilized on a solid surface wherein each molecule comprises a polynucleotide duplex covalently linked to form a hairpin loop structure, one end of which comprises a target polynucleotide and the array has a surface density which allows the target polynucleotides to be individually resolved (Abstract; page 6, second full paragraph; page 70, line 26-page 72, line 12; page 30, second paragraph and Fig. 13 and 14). It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to apply the high density teaching of Lockhart et al to the array of Lane et al to thereby provide for analysis of a large number of polynucleotides in a single analysis step for the obvious benefits of economy of time and labor. Additionally the courts have stated that a change in the size, shape and/or dimensions of a prior art device does not distinguish the device over the prior art.

In re Rinehart, 531 F.2d 1048, 189 USPQ 143 (CCPA 1976) ("mere scaling up of a prior art process capable of being scaled up, if such were the case, would not establish

Art Unit: 1634

patentability in a claim to an old process so scaled." 531 F.2d at 1053, 189 USPQ at 148.).

In Gardner v. TEC Systems, Inc., 725 F.2d 1338, 220 USPQ 777 (Fed. Cir. 1984), cert. denied, 469 U.S. 830, 225 USPQ 232 (1984), the Federal Circuit held that, where the only difference between the prior art and the claims was a recitation of relative dimensions of the claimed device and a device having the claimed relative dimensions would not perform differently than the prior art device, the claimed device was not patentably distinct from the prior art device. (see MPEP 2144.04 IV.A.)

Conclusion

- 12. No claim is allowed.
- 13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BJ Forman whose telephone number is (703) 306-5878. The examiner can normally be reached on 6:30 TO 4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones can be reached on (703) 308-1152. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-8724 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

BJ Forman, Ph.D. Patent Examiner Art Unit: 1634

September 4, 2002